Related references
Note: Only part of the references are listed.Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Tim Grob et al.
BLOOD (2022)
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
Andrew H. Matthews et al.
BLOOD ADVANCES (2022)
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Hartmut Doehner et al.
BLOOD (2022)
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Daniel A. Arber et al.
BLOOD (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax
Aleksander L. Chojecki et al.
LEUKEMIA RESEARCH (2022)
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - 2021 update on diagnosis, risk-stratification, and management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
Jan Philipp Bewersdorf et al.
BLOOD (2021)
A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Meagan A. Jacoby et al.
BLOOD (2021)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Courtney D. DiNardo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Edmond Chiche et al.
BLOOD ADVANCES (2021)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers
Eric J. Duncavage et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351)
Amandeep Salhotra et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease
Judith S. Hecker et al.
BLOOD (2021)
Relationship between clone metrics and clinical outcome in clonal cytopenia
Anna Galli et al.
BLOOD (2021)
Clonal hematopoiesis and associated diseases: A review of recent findings
Shuhei Asada et al.
CANCER SCIENCE (2021)
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
Rami Komrokji et al.
LEUKEMIA & LYMPHOMA (2021)
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet et al.
Lancet Haematology (2021)
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome
Laura W. Dillon et al.
JCO PRECISION ONCOLOGY (2021)
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Guillermo Garcia-Manero et al.
BLOOD (2020)
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
Brian J. Ball et al.
BLOOD ADVANCES (2020)
The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience
Armon Azizi et al.
LEUKEMIA & LYMPHOMA (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton et al.
NATURE GENETICS (2020)
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Fabio Forghieri et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
Nicholas J. Short et al.
BLOOD ADVANCES (2020)
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study
Jacqueline S. Garcia et al.
BLOOD (2020)
SF3B1-Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level
Rashmi Kanagal-Shamanna et al.
BLOOD (2020)
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
David A. Sallman et al.
BLOOD (2019)
Molecular pathogenesis of myelodysplastic syndromes with deletion 5q
Jung-hoon Lee et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Stefanie Jilg et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
Guillermo Montalban-Bravo et al.
BLOOD ADVANCES (2019)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang et al.
CELL DEATH & DISEASE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Dynamics of clonal evolution in myelodysplastic syndromes
Hideki Makishima et al.
NATURE GENETICS (2017)
The clonal origins of leukemic progression of myelodysplasia
T. Kim et al.
LEUKEMIA (2017)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Tetsuichi Yoshizato et al.
BLOOD (2017)
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Courtney D. DiNardo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Ashley A. Basiorka et al.
BLOOD (2016)
DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias
Liubin Yang et al.
CANCER CELL (2016)
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
Olga A. Guryanova et al.
NATURE MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Unraveling the Pathogenesis of MDS: The NLRP3 inflammasome and Pyroptosis Drive the MDS Phenotype
David A. Sallman et al.
FRONTIERS IN ONCOLOGY (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
R. Coleman Lindsley et al.
BLOOD (2015)
Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine: daunorubicin) Liposome Injection Versus Intensive Salvage Therapy in Adults With First Relapse AML
Jorge E. Cortes et al.
CANCER (2015)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Mingchao Xie et al.
NATURE MEDICINE (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers
Lan Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes
D. M. Murphy et al.
LEUKEMIA (2013)
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes
M. J. Walter et al.
LEUKEMIA (2013)
Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML
K. Takahashi et al.
LEUKEMIA (2013)
SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
Valeria Visconte et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
V. Visconte et al.
LEUKEMIA (2012)
Historical perspectives on myelodysplastic syndromes
David P. Steensma
LEUKEMIA RESEARCH (2012)
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Lambert Busque et al.
NATURE GENETICS (2012)
Clonal Architecture of Secondary Acute Myeloid Leukemia
Matthew J. Walter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida et al.
NATURE (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort
Xiaomei Ma et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Risks of myeloid malignancies in patients with autoimmune conditions
L. A. Anderson et al.
BRITISH JOURNAL OF CANCER (2009)
Cytogenetic features in myelodysplastic syndromes
Detlef Haase
ANNALS OF HEMATOLOGY (2008)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes:: evidence from a core dataset of 2124 patients
Detlef Haase et al.
BLOOD (2007)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
